Search Results
Your search for it matches 15746 pages
Showing 1651 - 1700MLH1 Methylation Status and Screenings for Colorectal or Endometrial Cancer
New research could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, according to a novel study published by Hitchins et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings suggest that the guidelines leave a...
New Tool May Help Physicians Pinpoint Gaps in Hematologic Malignancy Awareness
The novel Blood Cancer Awareness Measure tool could identify gaps in the public's knowledge of hematologic malignancy symptoms and aid in the development of future awareness campaigns designed to save lives, according to a new study published by Boswell et al in BMC Cancer and Whitaker et al in...
Expert Point of View: Kevin Kalinsky, MD, MS
Session co-moderator Kevin Kalinsky, MD, MS, the Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director of the Glenn Family Breast Center, and Director of Breast Medical Oncology at the Winship Cancer Institute of Emory University, Atlanta, offered his thoughts on PHERGain to The...
Overweight and Obese BMI May Be Linked to Adverse Treatment Outcomes in AYA Patients With ALL
An elevated body mass index (BMI) could potentially be associated with inferior treatment outcomes in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), according to a new study published by Shimony et al in Blood Advances. The findings may demonstrate the impact of...
Changing How Immune Checkpoint Inhibitors Are Delivered Could Reduce Costs by 14%, Study Finds
Investigators have found that millions of dollars could be saved annually across the Veterans Health Administration by reconsidering how immune checkpoint inhibitors are delivered, according to a new study published by Bryant et al in Health Affairs. The findings suggested that if vials of immune...
Fecal Microbiota Transplants Show Potential in Improving Melanoma Treatment
Researchers have found that fecal microbiota transplants from healthy donors may be safe and show potential in improving response rates to immunotherapy in patients with advanced melanoma, according to a phase I study published by Routy et al in Nature Medicine. Background While immunotherapy...
Expert Point of View: Erminia Massarelli, MD, PhD, MS
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Novel HPV-Targeted Agents Boost Efficacy of Pembrolizumab in Head and Neck Cancer, Two Studies Show
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
I Didn’t Want My Past to Become My Future
When I felt a large mass in my left breast as I was drying off from a shower on Thanksgiving Day, in 2007, I instinctively knew it was cancer. My mother had been diagnosed with breast cancer when she was 38, just 7 years older than I was at the time, and died 4 years later. I was 6 when she was...
Targeting Depressive Symptoms in Younger Breast Cancer Survivors
Guest Editor’s Note: Psychological distress is highly prevalent in women diagnosed with premenopausal breast cancer and has a significant negative impact on their quality of life. Thus, effective strategies are urgently needed to reduce the symptom burden. In this installment of The ASCO Post’s...
Retrospective View of Medical Dissection From May 1896
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Assessing Geriatric Oncology Practice in Portugal
The global population is aging rapidly. Currently, there are more than 703 million people worldwide aged 65 and older, representing 9.1% of the global population. It is estimated that this percentage will grow to 15.9%—1.5 billion people—by 2050.1 And with that growing aging population will come...
Olaparib With Abiraterone and Prednisone or Prednisolone for BRCA-Mutated, Metastatic Castration-Resistant Prostate Cancer
On May 31, 2023, the PARP inhibitor olaparib was approved by the U.S. Food and Drug Administration (FDA) with abiraterone and prednisone or prednisolone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.1...
Epcoritamab-bysp in Treatment of Relapsed or Refractory B-Cell Lymphomas
On May 19, 2023, epcoritamab-bysp was granted accelerated approval by the U.S. Food and Drug Administration for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two ...
ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...
How ASCO’s 2023 Breakthrough Meeting Is Putting a Spotlight on Cutting-Edge Advances in Cancer Care Technology and Innovation
After a 4-year hiatus because of the COVID-19 pandemic, ASCO’s Breakthrough meeting is returning to Asia from August 3–5, 2023, in Yokohama, Japan, and will also be livestreamed (https://conferences.asco.org/breakthrough/welcome). Launched in 2019 in Bangkok, Thailand, “Breakthrough is ASCO’s...
A Telephone-Based Weight-Loss Intervention Induced Clinically Meaningful Weight Loss in Patients With Breast Cancer and Overweight or Obesity
Jennifer A. Ligibel, MD, FASCO, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and colleagues conducted a randomized study to evaluate the impact of a telephone-based ...
Health Systems Strengthening Approach in the United States–Mexico Border Region Improved 5-Year Survival for Children With ALL
The implementation of a collaborative program between North American and Mexican medical institutions to achieve sustainable, high-quality care at a public hospital in the United States–Mexico border region for children with acute lymphoblastic leukemia (ALL) has resulted in significant improvement ...
Second Annual Conference at the Nixon Presidential Library and Museum Emphasizes Patients’ Concerns
On December 23, 1971, President Richard Nixon signed the National Cancer Act of 1971 into law, establishing a national cancer program that included the National Cancer Institute (NCI), other research institutes, and federal and nonfederal programs; funding for 15 new cancer research centers and...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
A European Leader in Surgical Oncology, Isabel T. Rubio, MD, PhD, Shares Her Story and Sheds Light on the Challenges Ahead
In this installment of The ASCO Post’s Global Oncology series, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Isabel T. Rubio, MD, PhD, Head of Breast Surgical Oncology at Clinica Universidad de Navarra, Madrid. Dr. Rubio is active in many societies and is a founding member and...
Expert Point of View: David A. Braun, MD, PhD
David A. Braun, MD, PhD, of Yale Cancer Center, was the formal discussant of the abstract on the 4-year follow-up of the CLEAR trial. “We have made remarkable progress [in advanced renal cell carcinoma] and are now in the combination era of immunotherapy-based therapy and immunotherapy-based...
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Expert Point of View: Mark Awad, MD, PhD
Formal discussant of KEYNOTE-671, Mark Awad, MD, PhD, of the Dana-Farber Cancer Institute, Boston, was optimistic about these data. “A hazard ratio of 0.58 for event-free survival and signals favoring overall survival in stage II to III non–small cell lung cancer [NSCLC] are truly impressive....
KEYNOTE-671 Trial: Perioperative Pembrolizumab Plus Chemotherapy Improves Outcomes in Stage II and III NSCLC
Neoadjuvant therapy with pembrolizumab plus platinum-based chemotherapy followed by surgery and then adjuvant pembrolizumab led to significantly improved event-free survival in patients with resectable stage II and III non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
A Call for Tailored Medical Services in Oncology Care for Older Deaf Patients
My father is deaf. Born deaf, he is now 75 years old. He uses his voice, but he sounds strange to a hearing person when he speaks. He uses lip-reading techniques to communicate. A year ago, he was diagnosed with Hodgkin lymphoma. We did his oncology itinerary together. My father cannot go alone to...
PROSPECT Trial: Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer
Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT...
Expert Point of View: Benjamin J. Solomon, MBBS, PhD
“Outcomes for patients with early-stage non–small cell lung cancer [NSCLC] remain poor despite potentially curative surgery and adjuvant cisplatin-based chemotherapy,” said formal abstract discussant Benjamin J. Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre and the University of Melbourne....
Adjuvant Osimertinib Improves Overall Survival in Resectable EGFR-Mutated NSCLC
The phase III ADAURA trial previously found that adjuvant use of osimertinib improved disease-free survival for completely resected EGFR-mutated non–small cell lung cancer (NSCLC) in patients with stage IB, II, or IIIA disease.1 The final analysis of ADAURA, which was presented at the 2023 ASCO...
Investigators Evaluate the Role of BMI in Outcomes in Patients With Head and Neck Cancer
Investigators have found that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those with a normal or obese BMI, according to a new study published...
Robotic-Assisted Resection of Challenging Gastric GISTs May Be Safe and Effective
Robot-assisted resection may be safe and effective at removing difficult-to-reach gastric gastrointestinal stromal tumors (GISTs), according to a novel study published by Lwin et al in the Journal of Surgical Research. Background For gastric GISTs, surgery is the standard treatment option; however, ...
Staging Laparoscopy May Help Identify Early Metastases in Patients With Pancreatic Cancer
Performing a minimally invasive staging laparoscopy on patients with newly diagnosed pancreatic cancer may help determine the stage and identify cancer metastases early, according to a novel study published by Gudmundsdottir et al in the Journal of the American College of Surgeons. The new findings ...
Personalized Dosing May Improve Outcomes in Patients With Prostate Cancer
Physicians may be able to personalize dosing intervals and consequently improve patient outcomes by monitoring early-response biomarkers in patients with prostate cancer who are undergoing treatment with lutetium (Lu)-177–PSMA, according to new findings presented by Emmett et al at the Society of...
CDCP1 May Be an Effective Therapeutic Target for Patients With Metastatic Bladder Cancer
Researchers have identified a new potential therapeutic target—the cell-surface tumor antigen CUB domain–containing protein 1 (CDCP1)—for patients with all subtypes of metastatic bladder cancer, according to findings presented by Chopra et al at the Society of Nuclear Medicine & Molecular...
Risk of Ovarian Cancer in Postmenopausal Patients With Polycystic Ovary Syndrome
Patients with polycystic ovary syndrome may not have a higher risk of ovarian cancer than those without the condition; however, postmenopausal patients with polycystic ovary syndrome may have twofold the risk of developing ovarian cancer, according to recent findings presented by Frandsen et al at...
Fertility in Female Survivors Treated for Hodgkin Lymphoma as Children
Female survivors treated for Hodgkin lymphoma may face declining fertility at a younger age, according to recent findings presented by Drechsel et al at the European Society of Human Reproduction and Embryology (ESHRE) 2023 Annual Meeting (Abstract O-083). The new research also suggested that the...
Study Identifies Potential Risk Factors for Early-Onset Colorectal Cancer in Male Patients
Researchers have identified seven potential risk factors for early-onset colorectal cancer in male patients and developed a novel risk evaluation model, according to a recent study published by Imperiale et al in Cancer Prevention Research. The findings may help 45- to 49-year-old patients accept...
LGBTQ+ Patients and Survivors of Cancer Expressed Concern Over Discrimination in Health-Care Settings, According to New Survey
About 50% of LGBTQ+ patients and survivors of cancer may be concerned about facing discrimination in a health-care setting, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). The new findings demonstrated that these concerns and experiences with...
Curettage and Cryosurgery May Be Effective for Patients With Basal Cell Carcinoma
The combination of curettage and cryosurgery may be a safe and effective treatment method for patients with basal cell carcinoma, according to a novel study published by Backman et al in the Journal of the American Academy of Dermatology. Background The incidence of skin cancer is continuing to...
Biden-Harris Administration Launches Initiative to Improve Cancer Outcomes in Low-Income Areas
On June 26, 2023, the Biden-Harris Administration awarded $50 million in the launch of the Persistent Poverty Initiative—a program designed to alleviate the cumulative effects of persistent poverty on cancer outcomes by increasing research capacity, fostering cancer prevention research, and...
FDA Approves Iopromide Injection for Contrast-Enhanced Mammography
Iopromide-300 and -370 (Ultravist), an iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography—making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of...
Potential Role of ChatGPT-4 in Selecting Appropriate Imaging Tests for Breast Cancer Screenings and Breast Pain
Investigators have found that artificial intelligence (AI) language models like OpenAI’s ChatGPT may accurately identify appropriate imaging tests for breast cancer screenings and breast pain, according to a recent study published by Rao et al in the Journal of the American College of Radiology....
Endometrial Cancer Risks and Trends Among Different Populations of African Descent
Women of African descent may have an elevated risk of being diagnosed with advanced endometrial cancer and developing aggressive tumors compared with White women, according to a recent study published by Medina et al in Cancer. Background Endometrial cancer is classified as endometrioid or the more ...
Pretherapy Imaging and Dosimetry May Inform Personalized Treatment Strategies for Patients With Refractory Differentiated Thyroid Cancer
A combination of pretherapy imaging and dosimetry may help patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following redifferentiation therapy, according to a novel study published by Taprogge et al in The Journal of Nuclear...
EGFR and ERBB2 Mutations May Be Associated With Lenvatinib-Resistant Hepatocellular Carcinoma
A genetic marker involving the EGFR and ERBB2 genes may be predictive of which patients with hepatocellular carcinoma are most likely to develop resistance to lenvatinib, according to a study published by Lim et al in Gastroenterology. The new findings could help researchers develop alternative...
Traditional Chinese Medicine Herbal Formula Suan Zao Ren Tang for Insomnia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
